The head-on clash between the ‘standard to first consider immune tolerance induction (ITI·antibody removal) therapies’ and the ‘due prescription rights of doctors·convenience in administration·saving NHI finances’ have received industry attention.

On the 3rd, the Health Insurance Review and Assessment Service (HIRA) held a Pediatric Department Special Review Committee to review medical benefit reimbursement of Hemlibra and disapproved its reimbursement. Therefore the clash between the industry·patient groups and the authorities in normalizing its reimbursement is deemed inevitable.

The reimbursement standard for Hemlibra that was implemented in February this year allows reimburse